INSMED Inc (INSM) stock
INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/3099% above fair value
$121.86−1.02 (-0.83%)
Close on Nov 17, 2026Market cap $26.73BP/E –Yield –
Insmed operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Insmed's operating cash flow for the twelve months ending Sep 30, 2026 was -$595.62M. For fiscal 2025 it was -$935.01M. The highest annual figure on record is -$7.72M in fiscal 2010.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$935.01M | – |
| FY2024 | Dec 31, 2024 | -$683.88M | – |
| FY2023 | Dec 31, 2023 | -$536.25M | – |
| FY2022 | Dec 31, 2022 | -$400.44M | – |
| FY2021 | Dec 31, 2021 | -$363.30M | – |
| FY2020 | Dec 31, 2020 | -$219.35M | – |
| FY2019 | Dec 31, 2019 | -$250.65M | – |
| FY2018 | Dec 31, 2018 | -$257.98M | – |
| FY2017 | Dec 31, 2017 | -$159.62M | – |
| FY2016 | Dec 31, 2016 | -$146.71M | – |
| FY2015 | Dec 31, 2015 | -$100.70M | – |
| FY2014 | Dec 31, 2014 | -$64.42M | – |
| FY2013 | Dec 31, 2013 | -$46.66M | – |
| FY2012 | Dec 31, 2012 | -$31.01M | – |
| FY2011 | Dec 31, 2011 | -$30.21M | – |
| FY2010 | Dec 31, 2010 | -$7.72M | – |
| FY2009 | Dec 31, 2009 | -$11.01M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$36.46M | – |
| Q2 FY2026 | Jun 30, 2026 | -$88.83M | – |
| Q1 FY2026 | Mar 31, 2026 | -$222.74M | – |
| Q4 FY2025 | Dec 31, 2025 | -$247.60M | – |
| Q3 FY2025 | Sep 30, 2025 | -$219.76M | – |
| Q2 FY2025 | Jun 30, 2025 | -$205.57M | – |
| Q1 FY2025 | Mar 31, 2025 | -$262.09M | – |
| Q4 FY2024 | Dec 31, 2024 | -$195.98M | – |
| Q3 FY2024 | Sep 30, 2024 | -$180.92M | – |
| Q2 FY2024 | Jun 30, 2024 | -$122.95M | – |
| Q1 FY2024 | Mar 31, 2024 | -$184.04M | – |
| Q4 FY2023 | Dec 31, 2023 | -$130.82M | – |
| Q3 FY2023 | Sep 30, 2023 | -$136.33M | – |
| Q2 FY2023 | Jun 30, 2023 | -$122.79M | – |
| Q1 FY2023 | Mar 31, 2023 | -$146.30M | – |
| Q4 FY2022 | Dec 31, 2022 | -$103.15M | – |
| Q3 FY2022 | Sep 30, 2022 | -$89.83M | – |
| Q2 FY2022 | Jun 30, 2022 | -$102.30M | – |
| Q1 FY2022 | Mar 31, 2022 | -$105.16M | – |
| Q4 FY2021 | Dec 31, 2021 | -$84.13M | – |
| Q3 FY2021 | Sep 30, 2021 | -$75.45M | – |
| Q2 FY2021 | Jun 30, 2021 | -$75.44M | – |
| Q1 FY2021 | Mar 31, 2021 | -$128.28M | – |
| Q4 FY2020 | Dec 31, 2020 | -$66.79M | – |
| Q3 FY2020 | Sep 30, 2020 | -$58.67M | – |
| Q2 FY2020 | Jun 30, 2020 | -$35.95M | – |
| Q1 FY2020 | Mar 31, 2020 | -$57.94M | – |
| Q4 FY2019 | Dec 31, 2019 | -$44.40M | – |
| Q3 FY2019 | Sep 30, 2019 | -$52.37M | – |
| Q2 FY2019 | Jun 30, 2019 | -$80.03M | – |
| Q1 FY2019 | Mar 31, 2019 | -$73.85M | – |
| Q4 FY2018 | Dec 31, 2018 | -$70.16M | – |
| Q3 FY2018 | Sep 30, 2018 | -$65.49M | – |
| Q2 FY2018 | Jun 30, 2018 | -$54.91M | – |
| Q1 FY2018 | Mar 31, 2018 | -$67.41M | – |
| Q4 FY2017 | Dec 31, 2017 | -$48.22M | – |
| Q3 FY2017 | Sep 30, 2017 | -$38.24M | – |
| Q2 FY2017 | Jun 30, 2017 | -$36.25M | – |
| Q1 FY2017 | Mar 31, 2017 | -$36.91M | – |
| Q4 FY2016 | Dec 31, 2016 | -$57.96M | – |
See a number that looks wrong?